Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: A pooled analysis from two randomised controlled trials

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 2, 2012, Pages 126-134

  Lichtenstein, G R ^a   Zakko, S ^b   Gordon, G L ^c   Murthy, U ^d   Sedghi, S ^e   Pruitt, R ^f   Merchant, K ^g   Bortey, E ^g   Forbes, W P ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Connecticut Gastroenterology Institute ^*  (United States)

^c Center for Digestive and Liver Diseases   (United States)

^d SYRACUSE VA MEDICAL CENTER   (United States)

^e Gastroenterology Associates of Central Georgia   (United States)

^f SAINT THOMAS HOSPITAL   (United States)

^g Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO;

ABDOMINAL PAIN; AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG GRANULE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCAPSULATION; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; HUMANS; KAPLAN-MEIER ESTIMATE; MESALAMINE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862531829     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05142.x     Document Type: Article

References (19)

1. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
2. Kane S, Huo D, Magnanti K,. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170-3. (Pubitemid 37248066)
3. Kane S, Huo D, Aikens J, Hanauer S,. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43. (Pubitemid 36126514)
4. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV,. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247-57.
5. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85.
6. Kane S, Shaya F,. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008; 53: 1020-4. (Pubitemid 351379831)
7. Kripalani S, Yao X, Haynes RB,. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-50. (Pubitemid 46513223)
8. Apriso [package insert]. Raleigh, NC: Salix Pharmaceuticals Inc., 2012.
9. Lichtenstein GR, Gordon GL, Zakko S, et al,. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis-a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010; 32: 990-9.
10. Sutherland LR, Martin F,. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987; 32: 64S-6S.
11. Rothman KJ, Michels KB,. The continuing unethical use of placebo controls. N Engl J Med 1994; 331: 394-8. (Pubitemid 24233862)
12. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B,. Placebo-controlled trials and the Declaration of Helsinki. Lancet 2002; 359: 1337-40. (Pubitemid 34310644)
13. Ellenberg SS, Temple R,. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000; 133: 464-70.
14. De Deyn PP, D'Hooge R,. Placebos in clinical practice and research. J Med Ethics 1996; 22: 140-6. (Pubitemid 26179006)
15. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 204-11.
16. Sandborn WJ, Korzenik J, Lashner B, et al,. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138: 1286-96.
17. Kane SV, Cohen RD, Aikens JE, Hanauer SB,. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33. (Pubitemid 32959535)
18. Kruis W, Jonaitis L, Pokrotnieks J, et al,. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-22.
19. Kane SV, Accortt NA, Magowan S, Brixner D,. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009; 29: 855-62.